Skip to main content

Table 3 Immunosuppressive treatment during the observation period

From: Association between body mass index and severe infection in older adults with microscopic polyangiitis: a retrospective cohort in Japan

 

Low BMI

(<  18.5)

Normal BMI (18.5–23.0)

High BMI

(>  23)

P value

Baseline

(n = 22)

(n = 53)

(n = 18)

 

 Prednisolone (mg/day)

30 (30–30)

30 (30–40)

34 (40–50)

< 0.001

  3rd month

(n = 17)

(n = 46)

(n = 17)

 

 Prednisolone (mg/day)

13 (10–15)

13 (10–15)

13 (10–15)

0.808

 Cumulative dose of prednisolone (g)

1.5 (1.5–1.6)

1.6 (1.4–1.8)

1.6 (1.4–1.9)

0.384

 Use of immunosuppressants [n (%)]

1 (5.9)

6 (13.0)

2 (12.5)

0.309

  6th month

(n = 15)

(n = 41)

(n = 15)

 

 Prednisolone (mg/day)

10 (8–10)

9 (8–10)

10 (7–10)

0.959

 Cumulative dose of prednisolone (g)

2.6 (2.5–3.1)

2.5 (2.1–3.0)

2.4 (2.0–3.2)

0.360

 Use of immunosuppressants [n (%)]

1 (6.7)

8 (19.5)

1 (6.7)

0.307

  1st year

(n = 13)

(n = 36)

(n = 13)

 

 Prednisolone (mg/day)

6 (5–8)

7 (5–8)

8 (5–8)

0.892

 Cumulative dose of prednisolone (g)

3.4 (3.1–4.1)

3.1 (2.7–43.9)

3.1 (2.7–3.8)

0.532

 Use of immunosuppressants [n (%)]

0 (0)

8 (22.2)

1 (7.7)

0.110

  2nd year

(n = 11)

(n = 26)

(n = 8)

 

 Prednisolone (mg/day)

5 (5–5)

5 (5–8)

5 (1–5)

0.267

 Cumulative dose of prednisolone (g)

5.1 (4.5–5.7)

5.1 (4.3–6.0)

5.0 (3.0–6.4)

0.906

 Use of immunosuppressants [n (%)]

1 (9.1)

11 (42.3)

1 (14.3)

0.081

  1. Median (interquartile range), categorical values are expressed as numbers (proportions)
  2. Abbreviations: BMI body mass index